[Form 4] CHEMED CORP Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Chemed VP and Chief Legal Officer Brian C. Judkins reported performance stock unit activity and related share movements. On February 13, 2026, 351 shares of capital stock were acquired at $469.56 per share upon PSU vesting, with 102 shares withheld to cover taxes, leaving 2,436 shares directly owned.
Two PSU tranches of 283 units each were exercised, and Judkins then received a new award of 908 performance stock units, bringing his direct PSU holdings to 2,306 units. One PSU program based on cumulative adjusted EPS paid out at 123% of target (124.1% including dividends) after achieving $67.67 versus a $66.46 maximum threshold, while a separate total shareholder return PSU program paid out at 0% of target.
Positive
- None.
Negative
- None.
Insider Trade Summary
566 shares exercised/converted
Mixed
6 txns
Insider
Judkins Brian C
Role
VP and Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Stock Units | 283 | $0.00 | -- |
| Exercise | Performance Stock Units | 283 | $0.00 | -- |
| Grant/Award | Performance Stock Units | 908 | $0.00 | -- |
| Exercise | Capital Stock | 351 | $469.56 | $165K |
| Exercise | Capital Stock | 0 | $469.56 | -- |
| Tax Withholding | Capital Stock | 102 | $469.56 | $48K |
Holdings After Transaction:
Performance Stock Units — 1,681 shares (Direct);
Capital Stock — 2,538 shares (Direct)
Footnotes (1)
- The number of performance stock units ("PSUs") that vested was based on the Company's cumulative adjusted earnings per share for the period January 1, 2023 through December 31, 2025. The actual performance of $67.67 exceeded the maximum payout threshold of $66.46 and therefore yielded an award of 123% of target; including the reinvestment of dividends paid during such period, the award is 124.1% of target. The number of PSUs that vested was based on the Company's achieving relative total shareholder returns for the period January 1, 2023 through December 31, 2025, compared to a defined peer group of companies. The Company's performance ranked in the 7th percentile of that group, yielding an award of 0%; including the reinvestment of dividends paid during such period, the award is 0% of target. Shares withheld to satisfy tax obligations in connection with vesting of PSUs. Each PSU reflects the contingent right to receive a variable number of shares of capital stock based on achieving performance goals. PSUs were settled in shares on their scheduled vesting date as determined by the Compensation Committee. PSUs awarded February 17, 2023 vest based on achievement of performance targets over a period of January 1, 2023 to December 31, 2025. The determination of the performance level is to be made by March 15, 2026. Each performance stock unit represents a contingent right to receive one share of Chemed Capital Stock Performance stock units vest based on the extent to which the Company achieves certain performance targets over a performance period of January 1, 2026 to December 31, 2028. The determination of the performance level is to be made by March 15, 2029 and earned shares to be delivered thereafter.
FAQ
What insider transactions did Chemed (CHE) executive Brian C. Judkins report?
Brian C. Judkins reported PSU vesting, share issuance, tax withholding, and a new PSU grant. He acquired 351 Chemed capital shares at $469.56 per share, had 102 shares withheld for taxes, and ended with 2,436 directly owned shares plus 2,306 performance stock units.
What performance stock unit awards did Brian C. Judkins receive from Chemed (CHE)?
Judkins reported a new grant of 908 performance stock units, taking his total direct PSU holdings to 2,306 units. These PSUs vest based on Chemed achieving defined performance targets over the January 1, 2026 to December 31, 2028 period, with performance determined by March 15, 2029.
How did Chemed’s EPS-based performance affect Brian C. Judkins’ PSU payout?
The EPS-based PSU award vested above target because Chemed’s cumulative adjusted earnings per share reached $67.67, exceeding the $66.46 maximum threshold. This performance produced a payout of 123% of target, or 124.1% of target after including reinvested dividends in the calculation.